Pharmacoeconomic models in rheumatology
Vol. 29 No. 4 (2021), Original Articles
Vol. 29 No. 4 (2021)

Pharmacoeconomic models in rheumatology

Original Articles
https://doi.org/10.35465/29.4.2021.pp15-39
Published October 24, 2021
Konstantin Tachkov
Faculty of Pharmacy, Medical University of Sofia
Vladimira Boyadzhieva
Medical Faculty, Medical University - Sofia
Zornitza Mitkova
Faculty of Pharmacy, Medical University of Sofia
Nikolay Stoilov
Medical Faculty, Medical University - Sofia
Guenka Petrova
Medical Faculty, Medical University - Sofia
PDF EN
PDF BG (Български)

Keywords

Pharmacoeconomics, modelling, rheumatology, cost-effectiveness

How to Cite

Tachkov, K., Boyadzhieva, V., Mitkova, Z., Stoilov, N., & Petrova, G. (2021). Pharmacoeconomic models in rheumatology. Rheumatology (Bulgaria), 29(4), 15-39. https://doi.org/10.35465/29.4.2021.pp15-39
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Pharmacoeconomic models of chronic diseases explore the development of the disease, patients’ pathways through it and calculate the cost-effectiveness of the therapy with different medicines.

The goal of the current study is to identify the pharmacoeconomic models used in rheumatology, their historical development and utilization.

Systematic search in PubMed was performed with key words „pharmacoeconomic, models, rheumatology, and cost-effectiveness “.

On total 58 manuscripts were identified, describing mainly the rheumatoid arthritis development. The first one in line is the ACCES model of rheumatoid arthritis which have been validated in Sweden, Norway, etc. This is one of the first Markov model in rheumatology. Biological medicines are in the primary area of interest for modelling their therapeutic results. During the latest year scientists are working for the development of the web based platform to forecast the biological therapy (model PREDIRA).

In alliance with other therapeutic areas with the development of artificial intelligence the pharmacoeconomic models is expected to increase, especially those build with data from real world clinical practice.

 

 

 

https://doi.org/10.35465/29.4.2021.pp15-39
PDF EN
PDF BG (Български)

References

  1. Milne R. J. Pharmacoeconomic Models in Disease Management. A Guide for the Novice or the Perplexed. Disease Management and Health Outcomes, 1998; 4: 119–134
  2. Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices - overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15(5):796-803.
  3. Hay J., Evaluation and review of pharmacoeconomic models. Expert Opinion on Pharmacotherapy 2004; 5 (9): 1867-80, DOI: 10.1517/14656566.5.9.1867
  4. Hill-McManus D., S. Marshall, J. Liu, R.J. Willke, D. A. Hughes. Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development. Clinical Pharmacology & Therapeutics 2021; 110 (1): 49-63 https://doi.org/10.1002/cpt.2051
  5. Carta A., C. Conversano. On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers. Front. Public Health, 2020 | https://doi.org/10.3389/fpubh.2020.569500
  6. Thomas D, Hiligsmann M, John D, Al Ahdab OG, Li H. Pharmacoeconomic analyses and modeling. In: Thomas D, editor. Clinical Pharmacy Education, Practice and Research. Amsterdam, NL: Elsevier (2019). p. 261–75. doi: 10.1016/B978-0-12-814276-9.00018-0
  7. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. (2002) 11:415–30. doi: 10.1002/hec.678
  8. Tachkov K., Modelling in pharmacoeconomics – application and types of models. Star, Sofia, 2020, ISBN: 978-619-7582-00-0
  9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
  10. Drummond M. F., M. J. Sculpher, G. W. Torrance et al. Methods for The Economic Evaluation of Health Care Programmes. Oxford Univ Press, London, 1998
  11. Kobelt G., L. Jönsson, P. Lindgren, A. Young, K. Eberhardt. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis Arthritis Rheum. 2002; 46(9): 2310-9. doi: 10.1002/art.10471.
  12. Kobelt G: The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003, 42(2):326–335.
  13. Hashemi-Meshkini A., , Shekoufeh Nikfar, Elizabeth Glaser, Ahmadreza Jamshidi, Seyed Alireza Hosseini, Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model V A LUE IN HEALTH REGIONAL ISSUES 9C (2016) 42 – 4 8)
  14. Scholz S., T. Mittendorf. Modeling rheumatoid arthritis using different techniques - a review of model construction and results. Health Economics Review, 2014, 4: 18
  15. Bessette L., N. Risebrough, N. Mittmann, J.-P.Roussy, J. Ho, G. Zlateva. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec health care system perspective. J MedEcon. 2009;12(3):246-58. doi: 10.3111/13696990903288970.
  16. Russell A., A. Beresniak, L. Bessette, B. Haraoui, P. Rahman, C. Thorne, R. Maclean, D. Dupont. ClinRheumatol. 2009 Apr;28(4):403-12. doi: 10.1007/s10067-008-1060-4.
  17. Puolakka K., H. Blåfield, M. Kauppi, R. Luosujärvi, R. Peltomaa, T. Leikola-Pelho, K. Sennfalt, A. Beresniak. Cost-effectiveness modellingofsequentialbiologicstrategies for thetreatmentofmoderate to severe rheumatoidarthritisinFinland. OpenRheumatol J. 2012;6:38-43. doi: 10.2174/1874312901206010038
  18. Baser O., A. Burkan, E. Baser, R. Koselerli, E. Ertugay, A. Altinba. Direct medical costs associated withrheumatoidarthritisinTurkey: analysis from National ClaimsDatabaseRheumatolInt. 2013;33(10):2577-84. doi: 10.1007/s00296-013-2782-4.
  19. Iannazzo S., M. Benucci, E.G.Favalli. Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequenceanalysisintheItaliansettingClinExpRheumatol. 2018;36(3):479-485.
  20. Purmonen Т., S. Törmälehto, H. Wahlman, K. Puolakka. Budgetimpactanalysisofsecukinumab versus adalimumabinthetreatmentofankylosingspondylitis. J MedEcon. 2019 Feb;22(2):151-157. doi: 10.1080/13696998.2018.1551227
  21. Svarvar P, Aly A. Use ofthe ACCES model to predictthehealtheconomicimpactofcelecoxibin patients withosteoarthritisorrheumatoidarthritisinNorway. Rheumatology (Oxford). 2000;39 (Suppl 2):43-50. doi: 10.1093/rheumatology/39.suppl_2.43.
  22. Welsing P.M.J, J.L. Severens, Ma. Hartman, A.M. vanGestel, P. L C M vanRiel, R. F J M Laan. The initial validation of a Markov model for the economice valuation of (new) treatments for rheumatoid arthritis. Pharmacoeconomics. 2006; 24(10):1011-20. doi: 10.2165/00019053-200624100-00008.
  23. Oh K-T, A H Anis, S-C Bae. Pharmacoeconomicanalysisofthiopurinemethyltransferasepolymorphismscreeningbypolymerasechainreaction for treatmentwithazathioprineinKorea. Rheumatology (Oxford) 2004 Feb;43(2):156-63. doi: 10.1093/rheumatology/keh001.
  24. Harrison M., C. Marra, K. Shojania, N. Bansback. Societalpreferences for rheumatoidarthritis treatments: evidencefrom a discretechoiceexperiment. Rheumatology (Oxford). 2015 Oct;54(10):1816-25. doi: 10.1093/rheumatology/kev113.
  25. Jutkowitz E., F. Alarid-Escudero, H. K. Choi, K. M. Kuntz, H. Jalal. PrioritizingFutureResearchonAllopurinol and Febuxostat for the Management ofGout: ValueofInformationAnalysis. Pharmacoeconomics. 2017;35(10):1073-1085. doi: 10.1007/s40273-017-0526-0
  26. Salinas-Escudero G., J.Vargas-Valencia, E.GabrielaGarcía-García, E.Munciño-Ortega, R. M.Galindo-Suárez. Cost-effectiveness analysisof etanercept comparedwithotherbiologictherapiesinthetreatmentofrheumatoidarthritis. RevMedInstMexSeguroSoc. Sep-Oct 2013;51(5):514-21.
  27. Tanaka E., E. Inoue, R. Yamaguchi, Y. Shimizu, A. Kobayashi, N. Sugimoto, D. Hoshi, K. Shidara, E. Sato, Y. Seto, A. Nakajima, S. Momohara, A. Taniguchi, H. Yamanaka. Pharmacoeconomicanalysisofbiologicaldiseasemodifyingantirheumaticdrugsin patients withrheumatoidarthritisbasedonreal-worlddatafromthe IORRA observationalcohortstudyinJapan. ModRheumatol. 2017;27(2):227-236. doi: 10.1080/14397595.2016.1205799.
  28. Hashemi-Meshkini А., S. Nikfar, E. Glaser, A. Jamshidi, S. A. Hosseini. Cost-EffectivenessAnalysisof Tocilizumab inComparisonwith Infliximab inIranianRheumatoidArthritis Patients with Inadequate Response to tDMARDs: A MultistageMarkov Model. Value Health RegIssues. 2016; 9:42-48. doi: 10.1016/j.vhri.2015.10.003.
  29. Incerti D., J. R..Curtis, J. Shafrin, D. N.Lakdawalla, J. P Jansen. A FlexibleOpen-SourceDecision Model for ValueAssessmentofBiologicTreatment for RheumatoidArthritis.Pharmacoeconomics. 2019;37(6):829-843. doi: 10.1007/s40273-018-00765-2.
  30. Tosh J., R. Archer, S. Davis, M. Stevenson, J. W. Stevens. Golimumab for thetreatmentofrheumatoidarthritisafterthefailureofpreviousdisease-modifyingantirheumaticdrugs: a NICE singletechnologyappraisal. Pharmacoeconomics. 2013;31(8):653-61. doi: 10.1007/s40273-013-0052-7
  31. Maetzel А., V. Strand, P. Tugwell, G. Wells, C. Bombardier. Costeffectivenessofadding leflunomide to a 5-year strategyofconventionaldisease-modifyingantirheumaticdrugsin patients withrheumatoidarthritis. ArthritisRheum. 2002; 47(6):655-61. doi: 10.1002/art.10793
  32. Clark W, P Jobanputra, P Barton, A Burls. The clinical and cost-effectiveness ofanakinra for thetreatmentofrheumatoidarthritisinadults: a systematicreview and economicanalysis. Health TechnolAssess. 2004;8(18):iii-iv, ix-x, 1-105. doi: 10.3310/hta8180.
  33. Alemao Е., M. J Al, A.A. Boonen, M. D. Stevenson, S.M. Verstappen, K. Michaud, M. E. Weinblatt, M. Rutten-vanMölken. Conceptual model for thehealthtechnologyassessmentofcurrent and novelinterventionsinrheumatoidarthritis. PLoSOne. 2018 Oct 5;13(10):e0205013. doi: 10.1371/journal.pone.0205013
  34. Ren S., I. Bermejo, E. Simpson, R. Wong, D. L. Scott, A. Young, M. Stevenson. Baricitinib for PreviouslyTreatedModerateor Severe RheumatoidArthritis: AnEvidenceReview Group Perspectiveof a NICE Single Technology Appraisal. Pharmacoeconomics. 2018 Jul;36(7):769-778. doi: 10.1007/s40273-018-0616-7.
  35. Uttley L., I.Bermejo, S. Ren, M.Martyn-StJames, R.Wong, D. L.Scott, A. Young, M.Stevenson. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-ModifyingAnti-rheumaticDrugs: AnEvidenceReview Group Perspectiveof a NICE Single Technology Appraisal.Pharmacoeconomics. 2018;36(9):1063-1072. doi: 10.1007/s40273-018-0639-0.
  36. E. Wehler, N. Boytsov, C. Nicolay, O. Herrera-Restrepo, S. Kowal. A BudgetImpact and CostPerAdditionalResponderAnalysis for Baricitinib for theTreatmentofModerate-to-Severe RheumatoidArthritisin Patients withan Inadequate Response to TumorNecrosisFactorInhibitorsinthe USA. Pharmacoeconomics. 2020 Jan;38(1):39-56. doi: 10.1007/s40273-019-00829-x.
  37. Bermejo I., S. Ren, E. Simpson, M. Clowes, D. L. Scott, A. Young, M. Stevenson. Sarilumab for Previously-TreatedModerateor Severe RheumatoidArthritis: AnEvidenceReview Group Perspectiveof a NICE Single Technology Appraisal. Pharmacoeconomics. 2018; 36 (12): 1427-1437. doi: 10.1007/s40273-018-0677-7.
  38. Schädlich Р. К., HenningZeidler, AngelaZink, ErikaGromnica-Ihle, MatthiasSchneider, ChristophStraub, Josef G Brecht, EduardHuppertz. Modellingcosteffectiveness and costutilityofsequential DMARD therapyincluding leflunomide for rheumatoidarthritisinGermany: II. The contributionof leflunomide to efficiency. Pharmacoeconomics. 2005;23(4):395-420. doi: 10.2165/00019053-200523040-00008.
  39. Nguyen C. M., M. Bounthavong, M. Mendes, M. Christopher, J. Tran, R. Kazerooni, A. Morreale. Costutilityoftumournecrosisfactor-α inhibitors for rheumatoidarthritis: anapplicationofBayesianmethods for evidencesynthesisin a Markov model. Pharmacoeconomics. 2012; 30 (7): 575-93. doi: 10.2165/11594990-000000000-00000.
  40. Yang H., D. Craig, D. Epstein, L. Bojke, K. Light, I. Bruce, M. Sculpher, N. Woolacott. Golimumab for thetreatmentofpsoriaticarthritis: a NICE singletechnologyappraisalPharmacoeconomics. 2012; 30 (4): 257-70. doi: 10.2165/11595920-000000000-00000.
  41. Navarro F, J M Martinez-Sesmero, A Balsa, C Peral, M Montoro, M Valderrama, S Gómez, F deAndrés-Nogales, M A Casado, ItziarOyagüez. Cost-effectiveness analysisoftreatmentsequencescontainingtofacitinib for thetreatmentofrheumatoidarthritisinSpain. ClinRheumatol. 2020; 39 (10): 2919-2930. doi: 10.1007/s10067-020-05087-3.
  42. Bermejo I., M. Stevenson, R. Archer, J. W. Stevens, E. Goka, M. Clowes, D. L. Scott, A. Young. CertolizumabPegol for TreatingRheumatoidArthritisFollowing Inadequate Response to a TNF-α Inhibitor: AnEvidenceReview Group Perspectiveof a NICE Single Technology Appraisal. Pharmacoeconomics. 2017; 35 (11): 1141-1151. doi: 10.1007/s40273-017-0521-5.
  43. Smolen L. J., J. C. Gahn., G. Mitri., A. Shiozawa. Febuxostatinthemanagementofgout: a cost-effectiveness analysis. J MedEcon. 2016;19(3):265-76. doi: 10.3111/13696998.2015.1116990.
  44. FatemiB., S.Rezaei, S.Taheri, F.Peiravian. Cost-effectiveness analysisoftofacitinibcomparedwithadalimumab and etanercept inthetreatmentof severe activerheumatoidarthritis; Iranianexperience. Expert RevPharmacoeconOutcomesRes. 2021 Aug;21(4):775-784. doi: 10.1080/14737167.2021.1834384.
  45. Barbieri M., F. Loconsole, A. Migliore, S. Capri. A cost-effectiveness and budgetimpactanalysisofapremilastin patients withpsoriasisintheItaliansetting. J MedEcon. 2020 Apr;23(4):362-370. doi: 10.1080/13696998.2019.1707209.
  46. Tran-Duy A., A. Boonen, W.Kievit, P.vanRiel, M.vandeLaar, J.Severens. Modellingoutcomesofcomplextreatmentstrategiesfollowing a clinicalguideline for treatmentdecisionsin patients withrheumatoidarthritis.Pharmacoeconomics. 2014 Oct;32(10):1015-28. doi: 10.1007/s40273-014-0184-4.
  47. Tian L., X. Xiong, Q. Guo, Y. Chen, L. Wang, P. Dong, AixiaMa. Cost-Effectiveness of Tofacitinib for Patients withModerate-to-Severe RheumatoidArthritisinChina. Pharmacoeconomics. 2020 Dec;38(12):1345-1358. doi: 10.1007/s40273-020-00961-z.
  48. Boyadzhieva, V., Stoilov, N., Ivanova, M. and Stoilov, R. 2019. Treatment of rheumatoid arthritis: csDMARDS versus bDMARDS. Prospective study to evaluate disease activity. Rheumatology (Bulgaria). 27, 1 (Apr. 2019), 3-15. DOI:https://doi.org/10.35465/27.1.2019.pp3-15.
  49. Boyadzhieva, V., Stoilov, N. and Stoilov, R. 2019. Assessment of health-related quality of life in patients with rheumatoid arthritis and analysis of its change during csDMARDS and bDMARDS therapy after one year of follow-up. Rheumatology (Bulgaria). 27, 3 (Sep. 2019), 29-43. DOI:https://doi.org/10.35465/27.3.2019.pp29-43.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.